Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

A study of filgrastim (rG-CSF) priming of etoposide/cisplatin in advanced non-small cell lung cancer.

Publication ,  Journal Article
Mehdi, SA; Perry, MC; Herndon, JE; Crawford, J; Young, R; Graziano, SL
Published in: J Interferon Cytokine Res
August 1998

A previous phase II study (CALGB 9132) of etoposide/cisplatin + rG-CSF in patients with advanced non-small cell lung cancer (NSCLC) showed a marked difference in the absolute neutrophil count (ANC) nadirs between courses 1 and 2. Median ANC nadirs for courses 1 and 2 were 200 and 2500, respectively, suggesting a priming effect for rG-CSF. The present study was designed to determine whether rG-CSF given prior to the first cycle of chemotherapy would decrease the severity and duration of neutropenia. Twelve patients with stage IIIB or IV NSCLC and performance status 0-1 received rG-CSF 5 microg/kg for 5 consecutive days starting 7 days before treatment with etoposide 200 mg/m2 on days 1-3 and cisplatin 35 mg/m2 on days 1-3, repeated every 3 weeks. Patients also received rG-CSF 5 microg/kg s.c. day 4 to postnadir ANC > 10,000. The median WBC nadir, ANC nadir, and platelet nadir after the first cycle of chemotherapy in the historical group (CALGB 9132) were 1300 cells/microl, 200 cells/microl, and 80,000 cells/microl, respectively. In the present study, the median WBC nadir, ANC nadir, and platelet nadir were 1300 cells/microl, 144 cells/microl, and 56,000 cells/microl, respectively. The median time for ANC to reach 10,000 cells/microl was 15 days in both the historical and the present study. For course 2, the WBC, ANC, platelet nadirs, and duration of grade 4 neutropenia were 2600, 1450, 70,000, and 0 days, respectively. This study failed to show a priming effect for rG-CSF when given in this dose and schedule.

Duke Scholars

Published In

J Interferon Cytokine Res

DOI

ISSN

1079-9907

Publication Date

August 1998

Volume

18

Issue

8

Start / End Page

623 / 627

Location

United States

Related Subject Headings

  • Recombinant Proteins
  • Neutropenia
  • Middle Aged
  • Male
  • Lung Neoplasms
  • Leukocyte Count
  • Immunology
  • Humans
  • Granulocyte Colony-Stimulating Factor
  • Filgrastim
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Mehdi, S. A., Perry, M. C., Herndon, J. E., Crawford, J., Young, R., & Graziano, S. L. (1998). A study of filgrastim (rG-CSF) priming of etoposide/cisplatin in advanced non-small cell lung cancer. J Interferon Cytokine Res, 18(8), 623–627. https://doi.org/10.1089/jir.1998.18.623
Mehdi, S. A., M. C. Perry, J. E. Herndon, J. Crawford, R. Young, and S. L. Graziano. “A study of filgrastim (rG-CSF) priming of etoposide/cisplatin in advanced non-small cell lung cancer.J Interferon Cytokine Res 18, no. 8 (August 1998): 623–27. https://doi.org/10.1089/jir.1998.18.623.
Mehdi SA, Perry MC, Herndon JE, Crawford J, Young R, Graziano SL. A study of filgrastim (rG-CSF) priming of etoposide/cisplatin in advanced non-small cell lung cancer. J Interferon Cytokine Res. 1998 Aug;18(8):623–7.
Mehdi, S. A., et al. “A study of filgrastim (rG-CSF) priming of etoposide/cisplatin in advanced non-small cell lung cancer.J Interferon Cytokine Res, vol. 18, no. 8, Aug. 1998, pp. 623–27. Pubmed, doi:10.1089/jir.1998.18.623.
Mehdi SA, Perry MC, Herndon JE, Crawford J, Young R, Graziano SL. A study of filgrastim (rG-CSF) priming of etoposide/cisplatin in advanced non-small cell lung cancer. J Interferon Cytokine Res. 1998 Aug;18(8):623–627.
Journal cover image

Published In

J Interferon Cytokine Res

DOI

ISSN

1079-9907

Publication Date

August 1998

Volume

18

Issue

8

Start / End Page

623 / 627

Location

United States

Related Subject Headings

  • Recombinant Proteins
  • Neutropenia
  • Middle Aged
  • Male
  • Lung Neoplasms
  • Leukocyte Count
  • Immunology
  • Humans
  • Granulocyte Colony-Stimulating Factor
  • Filgrastim